Startup Bangladesh’s First Portfolio Exit Comes as PulseTech Scales and Prepares for Series A

The government-backed VC says its investment in the pharmaceutical distribution startup has generated a multi-fold return, while PulseTech targets international expansion after scaling annualized revenue to US$150 million

Startup Bangladesh, the country’s government-backed venture capital fund, has recorded its first portfolio exit and multi-fold investment return through pharmaceutical distribution startup PulseTech, two years after making its initial investment in the company. PulseTech says its annualized revenue has grown from US$2 million to US$150 million since receiving its first institutional investment in 2024, while remaining profitable. The company now serves more than 14,000 retail pharmacies, collectively reaching more than 8.5 million people in Dhaka, and is preparing to raise a Series A round as it expands beyond Bangladesh.

Startup Bangladesh, which operates under Bangladesh’s ICT Division, has invested in 36 startups since its inception. The fund did not disclose the amount initially invested in PulseTech, the proceeds from the exit, or the precise return multiple, but described the transaction as the first multi-fold return in its portfolio.

The development comes at a time when Bangladesh’s startup ecosystem is still working to build deeper pools of capital and more consistent exit pathways. The country recorded US$124 million in startup funding across 12 deals in 2025, but the figure was heavily concentrated in a US$110 million transaction associated with the formation of SILQ Group. More than 90% of funding value came from late-stage and strategic transactions, while early-stage activity remained constrained.

Against that backdrop, a realized return from a government-backed investor provides an important, though still early, test of whether public venture capital can produce both ecosystem impact and commercial outcomes.

PulseTech becomes an early proof point for Startup Bangladesh

Startup Bangladesh’s investment thesis for PulseTech was built around three factors: the founding team, the size and fragmentation of Bangladesh’s pharmaceutical distribution market, and a technology-led model that could scale while remaining profitable.

Nurul Hai, CEO and Managing Director of Startup Bangladesh, explained the rationale while conversing with AsiaTechDaily.

“When we invested in PulseTech in 2024, our conviction was based on three factors: a strong founding team, a large and fragmented pharmaceutical distribution market, and a technology-led model with a clear path to scale and profitability.

“In hindsight, execution has been the defining factor. The team has successfully converted a large market opportunity into rapid, disciplined growth while maintaining commercial sustainability. This combination of scale, profitability, and execution validated our original investment thesis.

“For Startup Bangladesh, this exit goes beyond a single company. It shows that high-growth technology businesses can be built in Bangladesh, that institutional capital can generate strong returns here, and that backing capable local founders can create meaningful value. PulseTech is an important proof point for the broader opportunity Bangladesh offers.”

That broader ecosystem context is important. Bangladesh’s startup funding market remains relatively small compared with larger South and Southeast Asian markets, and its recent funding numbers have been driven by a limited number of large transactions. LightCastle’s 2025 report also found that roughly 99% of the year’s startup capital came from global investors, underscoring the importance of creating stronger domestic investment and exit mechanisms.

One successful investment does not resolve those structural challenges, but it provides an example of capital being recycled through an actual portfolio outcome rather than remaining tied to unrealized valuations.

PulseTech targets fragmentation in pharmaceutical distribution

PulseTech’s business is built around a structural problem in Bangladesh’s pharmaceutical supply chain. The country’s pharmaceutical industry is relatively developed, with local manufacturers meeting approximately 98% of domestic medicinal demand. The pharmaceutical market is projected at around US$6 billion, according to Bangladesh Investment Development Authority data.

PulseTech operates downstream from manufacturers and focuses on the fragmented network of independent pharmacies. Its MedBox platform allows smaller pharmacies to order medicines digitally and receive them through a same-day delivery network. The company has added several services around that core distribution business, including embedded financing, pharmacy software and ONE Pharmacy, a franchise network intended to bring independent pharmacies under a common brand.

The model is therefore broader than pharmaceutical delivery. PulseTech is attempting to provide procurement, financing, software and branding infrastructure to smaller pharmacies that traditionally source medicines from multiple distributors or wholesale markets. That fragmentation creates operational inefficiencies and can complicate efforts to ensure that medicines moving through the supply chain are authentic. PulseTech says its network now serves more than 14,000 pharmacies and helps them access authentic medicines. The company also says its current scale represents less than 5% of Bangladesh’s pharmaceutical market, suggesting significant room for domestic expansion. That figure is company-provided and is not independently verified.

From $2M to $150M in annualized revenue

The pace of PulseTech’s growth is central to the investment return. According to the company, it increased annualized revenue from US$2 million in 2024 to US$150 million in 2026, representing a substantial increase within two years. It also reports an average month-on-month revenue growth rate of 20% and says it has remained profitable. The company previously raised a US$3 million pre-Series A round in 2025, co-led by Iterative and Accelerating Asia Ventures, to expand its pharmaceutical distribution platform. The current Series A process represents the next stage of that capital strategy.

PulseTech’s growth is notable because Bangladesh’s startup funding environment has become more selective. LightCastle’s latest ecosystem report found that 2025 funding increased sharply in headline terms, but the market was dominated by a handful of large transactions rather than broad-based growth across startup stages. For PulseTech, profitability provides a different fundraising proposition.

Kazi Ashikur Rasul, Co-founder and CEO of PulseTech, told AsiaTechDaily that the company’s approach to fundraising has changed since its first institutional round.

“In 2024, we raised capital to fuel early growth and prove the scalability of our model. Within two years of our first institutional investment, we scaled from US$2 million to US$150 million in annualized revenue. Today, the business is profitable, so this round is a strategic choice rather than a necessity. We’re raising to bring in the right partners for the next phase, investors who understand emerging markets and can open doors as we expand internationally.

“Beyond capital, what we really want is engagement. We actively ask investors to dig into our financials and challenge us. When someone asks the hard questions, it sharpens our thinking and often confirms we’re on the right track. So, we look for partners who stay involved, understand the details, and help us navigate new markets.”

The distinction could become important as PulseTech enters markets outside Bangladesh. Growth capital can finance expansion, but internationalization also requires regulatory knowledge, local partnerships and an understanding of different pharmaceutical procurement and retail structures.

Saudi Arabia will test whether the model travels

PulseTech plans to make Saudi Arabia its first international market, marking a significant shift from scaling within Bangladesh to exporting its operating model. Saudi Arabia has been investing in healthcare infrastructure and pharmaceutical localization as part of its broader Vision 2030 agenda. Its pharmaceutical market also has a different structure from Bangladesh, with greater integration into a regulated healthcare system and a stronger presence of large-scale pharmaceutical and healthcare organizations.

For PulseTech, that creates both an opportunity and a test. The company has demonstrated that its technology-enabled distribution model can scale within Bangladesh’s fragmented pharmacy network. Replicating that model internationally will require adapting its procurement, financing, software and pharmacy services to local regulations and market structures.

PulseTech says it is targeting US$1 billion in revenue as it expands across Bangladesh and enters international markets, although it has not provided a timeframe for reaching that target.

What the return means for Bangladesh’s startup ecosystem

The significance of Startup Bangladesh’s PulseTech return extends beyond the individual investment. Venture ecosystems ultimately depend on a cycle in which capital is deployed into startups, successful companies generate liquidity for investors, and those returns can support another generation of investments. Bangladesh’s recent funding data shows why that cycle remains important. In 2025, the country recorded 12 startup deals totaling US$124 million, while early-stage investment remained relatively limited and capital was heavily concentrated in larger transactions.

Startup Bangladesh’s first portfolio return offers an early example of what that cycle can look like. But the more consequential test may now belong to PulseTech. The company must demonstrate that rapid domestic growth can translate into sustainable international expansion, while its Series A investors will be evaluating whether the Bangladesh-built model can support a much larger business.

Startup Bangladesh has demonstrated that one government-backed investment can generate a commercial return. PulseTech’s next phase will test whether a technology-enabled pharmaceutical distribution model built around Bangladesh’s market fragmentation can become an exportable business model. If it can, the significance of the investment may extend beyond one successful portfolio outcome to a broader case for building globally scalable companies from Bangladesh.

Quick Takeaways

• Startup Bangladesh has recorded its first portfolio exit and multi-fold investment return through PulseTech, two years after investing in the company.
• The government-backed VC says it has invested in 36 startups since its inception.
• PulseTech’s annualized revenue grew from US$2 million to US$150 million between 2024 and 2026, while the company says it remained profitable.
• PulseTech now serves more than 14,000 retail pharmacies, collectively reaching over 8.5 million people in Dhaka.
• Its core platform, MedBox, helps independent pharmacies source authentic medicines through digital ordering and same-day delivery.
• PulseTech also offers embedded financing, pharmacy software and ONE Pharmacy, a franchise network for independent pharmacies.
• The company says it currently serves less than 5% of Bangladesh’s roughly US$6 billion pharmaceutical market, leaving room for further domestic expansion.
• Startup Bangladesh’s Nurul Hai said the original investment thesis centered on the founding team, the fragmented pharmaceutical distribution market, and a technology-led model with a path to scale and profitability.
• PulseTech is now preparing for a Series A, which CEO Kazi Ashikur Rasul says is intended primarily for growth and strategic partnerships rather than immediate capital needs.
• The company wants Series A investors who can provide emerging-market expertise, international connections and active engagement, beyond capital.
• Saudi Arabia will be PulseTech’s first international market, marking a shift from domestic scaling to international expansion.
• PulseTech is targeting US$1 billion in revenue as it expands in Bangladesh and internationally, although no timeframe was provided.
• The broader significance is that the return provides an early proof point for Bangladesh’s public venture-capital model, but one successful exit does not by itself resolve the country’s broader challenges around later-stage funding and exits.